Animal Model

Global Animal Model Market to Reach US$3.7 Billion by 2030

The global market for Animal Model estimated at US$2.4 Billion in the year 2024, is expected to reach US$3.7 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Mice, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Rat segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$654.6 Million While China is Forecast to Grow at 11.8% CAGR

The Animal Model market in the U.S. is estimated at US$654.6 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$788.3 Million by the year 2030 trailing a CAGR of 11.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Animal Model Market - Key Trends & Drivers Summarized

Why Is the Demand for Animal Models Rising in Biomedical Research?

The growing reliance on animal models in biomedical and pharmaceutical research is a key driver of market growth. As the prevalence of chronic diseases such as cancer, diabetes, and neurodegenerative disorders continues to rise, there is an increasing need for preclinical studies to evaluate the safety and efficacy of new therapeutics. Animal models play a crucial role in translational research by providing a biological system that closely mimics human physiology and pathology, allowing researchers to gain critical insights into disease mechanisms. The expanding focus on personalized medicine and gene therapy has further accelerated demand for genetically modified animal models that can simulate specific human genetic conditions. Additionally, regulatory bodies such as the FDA and EMA mandate preclinical testing using animal models before approving drugs for human trials, further cementing their importance in the drug development pipeline.

How Are Technological Advancements Shaping the Animal Model Market?

Innovations in genetic engineering and biotechnology are revolutionizing the development of more precise and reliable animal models for research applications. Advances in CRISPR-Cas9 gene-editing technology have enabled the creation of genetically modified animal models with high specificity, allowing researchers to study the role of specific genes in disease development and progression. The integration of artificial intelligence (AI) and data analytics in animal research is also improving study accuracy by enabling the automated tracking of physiological and behavioral responses. Furthermore, the increasing adoption of 3D bioprinting and organ-on-chip technologies is complementing traditional animal models, enhancing the ability to conduct more accurate and ethically responsible research. These technological advancements are not only improving the reproducibility and reliability of preclinical studies but are also opening up new opportunities in regenerative medicine and toxicology testing.

What Challenges and Opportunities Exist in the Animal Model Market?

The animal model market faces several challenges, including ethical concerns, regulatory scrutiny, and the availability of alternative testing methods. Ethical debates surrounding the use of animals in research have led to stringent guidelines and increased pressure from animal rights organizations, prompting the industry to explore non-animal alternatives such as in vitro models and computer simulations. Regulatory agencies are imposing stricter compliance requirements related to animal welfare, further complicating the market landscape for pharmaceutical and research institutions. However, these challenges present opportunities for market players to develop more refined and humane animal models that minimize suffering while maximizing research outcomes. The increasing adoption of humanized animal models, which incorporate human cells or genes to better replicate human conditions, is also opening new avenues for research in oncology, immunology, and infectious diseases.

What Are the Key Factors Driving Growth in the Animal Model Market?

The growth in the Animal Model market is driven by several factors, including the rising demand for novel therapeutics, expanding government funding for biomedical research, and the increasing prevalence of zoonotic diseases that require animal model-based studies. Pharmaceutical companies are investing heavily in preclinical research to develop innovative drugs and biologics, fueling demand for sophisticated animal models that can provide reliable efficacy and safety data. The growing focus on vaccine development, particularly in light of emerging infectious diseases and global health threats, is further boosting the market. Additionally, the rising use of animal models in veterinary research to improve livestock productivity and companion animal health is contributing to market expansion. With continuous advancements in genetic engineering and molecular biology, the animal model market is poised for sustained growth, offering new opportunities for research institutions and industry stakeholders worldwide.

SCOPE OF STUDY:

The report analyzes the Animal Model market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Animal Type (Mice, Rat, Guinea Pig, Hamster, Other Animal Types); Application (Cancer Application, Infectious Disease Application, Immunological disease Application, Other Applications); End-Use (Pharma and Biotech Companies End-Use, Contract Research Organizations End-Use, Academic Research Institutes End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Biocytogen Boston Corp.
• Charles River Laboratories International, Inc.
• Crown Bioscience Inc.
• Cyagen US Inc.
• Genoway S.A.
• Hera Biolabs
• InnoSer Belgie NV
• Inotiv, Inc.
• Janvier Labs
• Ozgene Pty Ltd.
• Taconic Biosciences, Inc.
• The Jackson Laboratory

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.